ImmuCell

Company ICCC

Last mentioned: Mar 4, 2026

Stories mentioning ImmuCell 2

earnings Neutral

ImmuCell and Pinetree Capital Reveal 2025 Results Amid Scaling Shift

ImmuCell (ICCC) has issued its preliminary 2025 financial results, highlighting a year of operational scaling for its bovine immunity products. Simultaneously, major shareholder Pinetree Capital Ltd released audited figures and expanded its board, signaling a period of strategic consolidation for the animal health biotech and its primary backer.

2 sources
market-trends Neutral

ImmuCell 2025 Results Highlight Production Scaling and Strategic Backing

ImmuCell (NASDAQ: ICCC) has reported its unaudited 2025 financial results, highlighting a pivotal year of production expansion and backlog reduction for its bovine immunology products. The results were released alongside strategic updates from Pinetree Capital, a major institutional investor, signaling a period of maturing corporate governance.

2 sources